Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

Oncotarget

Volumn 8, Issue 39, 2017, Pages 64670-64684

  Glubb, Dylan M ^a   Johnatty, Sharon E ^a   Quinn, Michael C J ^a   O'Mara, Tracy A ^a   Tyrer, Jonathan P ^b   Gao, Bo ^c,d   Fasching, Peter A ^e,f   Beckmann, Matthias W ^f   Lambrechts, Diether ^g,h   Vergote, Ignace ⁱ   Edwards, Digna R Velez ^j   Beeghly Fadiel, Alicia ^k   Benitez, Javier ^l   Garcia, Maria J ^l   Goodman, Marc T ^m   Thompson, Pamela J ^m   Dörk, Thilo ⁿ   Dürst, Matthias ^o   Modungo, Francesmary ^p,q,r   Moysich, Kirsten ^s   Heitz, Florian ^t,u   du Bois, Andreas ^t,u   Pfisterer, Jacobus ^v   Hillemanns, Peter ⁿ   Karlan, Beth Y ^m   Lester, Jenny ^m   Goode, Ellen L ^w   Cunningham, Julie M ^w   Winham, Stacey J ^w   Larson, Melissa C ^w   McCauley, Bryan M ^w   Kjær, Susanne Krüger ^x,y   Jensen, Allan ^y   Schildkraut, Joellen M ^z   Berchuck, Andrew ^aa   Cramer, Daniel W ^ab   Terry, Kathryn L ^ab,ac   Salvesen, Helga B ^ad,ae   Bjorge, Line ^ad,ae   Webb, Penny M ^a   Grant, Peter ^af   Pejovic, Tanja ^ag,ah   Moffitt, Melissa ^ag,ah   Hogdall, Claus K ^x   Hogdall, Estrid ^x,y   Paul, James ^ai   Glasspool, Rosalind ^ai   Bernardini, Marcus ^aj   Tone, Alicia ^aj   Huntsman, David ^ak   Woo, Michelle ^al   de Fazio, Anna ^c,d   Kennedy, Catherine J ^c,d   Pharoah, Paul D P ^b   MacGregor, Stuart ^a   Chenevix Trench, Georgia ^a   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l Structural Biology and Biocomputing Programme   (Spain)

^m CEDARS SINAI MEDICAL CENTER   (United States)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^p UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

^t KLINIKEN ESSEN MITTE   (Germany)

^u DR HORST SCHMIDT KLINIKEN   (Germany)

^v Zentrum für Gynäkologische Onkologie   (Germany)

^w MAYO CLINIC   (United States)

^x UNIVERSITY OF COPENHAGEN   (Denmark)

^y DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^z UNIVERSITY OF VIRGINIA   (United States)

^aa DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ab BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ac HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ad HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^ae UNIVERSITY OF BERGEN   (Norway)

^af MERCY HOSPITAL FOR WOMEN   (Australia)

^ag OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ah OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ai BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^aj PRINCESS MARGARET HOSPITAL   (Canada)

^ak UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^al BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^am UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Gene regulation; Genetic association; Meta analysis; Ovarian cancer outcome

Indexed keywords

GENOMIC DNA;

ARTICLE; BIOINFORMATICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN; CHROMATIN INTERACTION; CHROMOSOME 19P; CHROMOSOME 1Q; CONTROLLED STUDY; DNA STRUCTURE; FALSE POSITIVE RESULT; FEMALE; FUNCTIONAL GENETIC ANALYSIS; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIATION; GERMLINE VARIANT; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEF2D GENE; MOLECULAR GENETICS; OVARIAN CANCER CELL LINE; OVARY CANCER; OVCAR8 CELL LINE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PUTATIVE REGULATORY ELEMENT; SURVIVAL RATE; SURVIVAL TIME; ZNF100 GENE;

EID: 85030120544     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.18501     Document Type: Article

References (31)

1. Dinkelspiel HE, Champer M, Hou J, Tergas A, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL, Wright JD. Long-term mortality among women with epithelial ovarian cancer. Gynecologic Oncology. 2015; 138:421-428.
2. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecologic Oncology. 2015; 138:750-756.
3. Johnatty SE, Tyrer JP, Kar S, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, et al. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res. 2015; 21:5264-5276.
4. Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, Wingett SW, Andrews S, Grey W, Ewels PA, Herman B, Happe S, Higgs A, et al. Mapping long-range promoter contacts in human cells with highresolution capture Hi-C. Nat Genet. 2015; 47:598-606.
5. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, Poh HM, Goh Y, Lim J, Zhang J, Sim HS, Peh SQ, Mulawadi FH, et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell. 2012; 148:84-98.
6. Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, Trowbridge CA, Maller JB, Tukiainen T, Lek M, Ward LD, Kheradpour P, Iriarte B, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 2015; 348:648-660.
7. Hou C, Dale R, Dean A. Cell type specificity of chromatin organization mediated by CTCF and cohesin. Proc Natl Acad Sci U S A. 2010; 107:3651-3656.
8. Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol. 2015; 16:144-154.
9. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013; 155:934-947.
10. Ørom UA, Shiekhattar R. Long non-coding RNAs and enhancers. Curr Opin Genet Dev. 2011; 21:194-198.
11. Li S, Weidenfeld J, Morrisey EE. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol. 2004; 24:809-822.
12. Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH, Kim KH, Suh DS, Kim JH. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget. 2016; 7:3506-3519. doi: 10.18632/oncotarget.6510.
13. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19:197-208.
14. Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, Casey G, Hunter DJ, Sellers TA, Gruber SB, Dunning AM, Michailidou K, Fachal L, et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2017; 26:126-135.
15. Breitbart RE, Liang CS, Smoot LB, Laheru DA, Mahdavi V, Nadal-Ginard B. A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development. 1993; 118:1095-1106.
16. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, Xia F, Shan J, Shen J, Yang Z, Bie P, Cui Y, Bian XW, et al. Overexpression of the transcription factor MEF2D in hepatocellular cancer sustains malignant character by suppressing G2/M transition genes. Cancer Research. 2014; 74:1452-62.
17. Yu H, Sun H, Bai Y, Han J, Liu G, Liu Y, Zhang N. MEF2D overexpression contributes to the progression of osteosarcoma. Gene. 2015; 563:130-135.
18. Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F, Shan J, Chen J, Li F, Liu L, Liu C, Xu Y, Jiang L, et al. MEF2D transduces microenvironment stimuli to ZEB1 to promote epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Research. 2016; 76:5054-67.
19. Chen W, Xiang J, Chen DF, Ni BB, Chen H, Fan XJ, Wang PN, Song SX, Fang LK, Xiao HY, Wang L, Wang JP. Screening for differentially methylated genes among human colorectal cancer tissues and normal mucosa by microarray chip. Mol Biol Rep. 2013; 40:3457-3464.
20. Craig DW, Liang W, Venkata Y, Kurdoglu A, Aldrich J, Auclair D, Allen K, Harrison B, Jewell S, Kidd PG, Correll M, Jagannath S, Siegel DS, et al. Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. Blood. 2013; 122:532-532.
21. Rink L, Ochs MF, Zhou Y, von Mehren M, Godwin AK. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PloS one. 2013; 8:e54477.
22. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F. Chromosome 19 rearrangements in ovarian carcinomas: Zinc finger genes are particularly targeted. Genes, Chromosomes and Cancer. 2014; 53:558-567.
23. Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, Laframboise T, Brown M, Tyekucheva S, Freedman ML. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell. 2013; 152:633-641.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81:559-575.
25. Tan-Wong SM, French JD, Proudfoot NJ, Brown MA. Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene. Proc Natl Acad Sci U S A. 2008; 105:5160-5165.
26. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, Betts JA, Carroll T, Bailey PJ, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet. 2013; 92:489-503.
27. Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM, Kaufmann S, Beesley J, Canisius S, et al. Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. Am J Hum Genet. 2015; 96:5-20.
28. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015; 31:3555-3557.
29. Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, Henderson MJ, Russell AJ, Hedditch EL, Emmanuel C, Fereday S, Webb PM, Group AOCS, et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol. 2013; 131:8-14.
30. French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget. 2016; 7:6353-6368. doi: 10.18632/oncotarget.7047.
31. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009; 5:e1000529.